These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8040107)

  • 1. The fluoroquinolones as treatment for infections caused by gram-positive bacteria.
    Cruciani M; Bassetti D
    J Antimicrob Chemother; 1994 Mar; 33(3):403-17. PubMed ID: 8040107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of quinolones against gram-positive cocci: clinical features.
    Giamarellou H
    Drugs; 1995; 49 Suppl 2():58-66. PubMed ID: 8549418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
    Fong IW
    Clin Invest Med; 1989 Feb; 12(1):44-9. PubMed ID: 2646054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer quinolones in the treatment of continuous ambulatory peritoneal dialysis (CAPD) related infections.
    Nikolaidis P
    Perit Dial Int; 1990; 10(2):127-33. PubMed ID: 2085597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.
    Maschmeyer G
    Drugs; 1993; 45 Suppl 3():73-80. PubMed ID: 7689455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of temafloxacin for gram-positive pathogens.
    Bille J; Glauser MP
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():9-14. PubMed ID: 1664835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.
    Aoun M; Van der Auwera P; Varthalitis I; Bourguignon AM; Janssen M; Daneau D; Meunier F
    Support Care Cancer; 1994 May; 2(3):191-6. PubMed ID: 8032706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.
    Del Favero A; Menichetti F
    Eur J Cancer; 1993; 29A Suppl 1():S2-6. PubMed ID: 8427721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of quinolones in staphylococcal infection.
    Shah PM
    J Chemother; 1989 Aug; 1(4):253-6. PubMed ID: 2809692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
    Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.
    Lipsky BA; Miller B; Schwartz R; Henry DC; Nolan T; McCabe A; Magner DJ; Talbot GH
    Clin Ther; 1999 Apr; 21(4):675-90. PubMed ID: 10363733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the fluoroquinolone antibiotics.
    Just PM
    Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients.
    Cruciani M; Malena M; Bosco O; Nardi S; Serpelloni G; Mengoli C
    J Clin Oncol; 2003 Nov; 21(22):4127-37. PubMed ID: 14615441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years.
    Bouza P; García Falcón T; Pérez Fontán M; Rodríguez-Carmona A; López Vázquez M; Tresancos C; Valdés F
    Adv Perit Dial; 1996; 12():185-8. PubMed ID: 8865898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of fluoroquinolones in skin and skin structure infections.
    Blondeau JM
    Am J Clin Dermatol; 2002; 3(1):37-46. PubMed ID: 11817967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis.
    Greenberg RN; Newman MT; Shariaty S; Pectol RW
    Antimicrob Agents Chemother; 2000 Jan; 44(1):164-6. PubMed ID: 10602739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.